Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence...

por Maurer, M., Sofen, H., Ortiz, B., Kianifard, F., Gabriel, S., Bernstein, J.A.
Publicado 2017

Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis: Letter to the Editor

por Gooderham, M., Elewski, B.E., Pariser, D.M., Sofen, H., Mendelsohn, A.M., Rozzo, S.J., Li, Q.
Publicado 2019

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials

por Blauvelt, A., Sofen, H., Papp, K., Gooderham, M., Tyring, S., Zhao, Y., Lowry, S., Mendelsohn, A., Parno, J., Reich, K.
Publicado 2019

Three‐year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial

por Warren, R. B., Lebwohl, M., Sofen, H., Piguet, V., Augustin, M., Brock, F., C. Arendt, Fierens, F., Blauvelt, A.
Publicado 2021

Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

por Griffiths, C.E.M., Vender, R., Sofen, H., Kircik, L., Tan, H., Rottinghaus, S.T., Bachinsky, M., Mallbris, L., Mamolo, C.
Publicado 2016

Noninvasive genomic detection of melanoma

por Wachsman, W, Morhenn, V, Palmer, T, Walls, L, Hata, T, Zalla, J, Scheinberg, R, Sofen, H, Mraz, S, Gross, K, Rabinovitz, H, Polsky, D, Chang, S
Publicado 2011

Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐wee...

por Blauvelt, A., Reich, K., Mehlis, S., Vanaclocha, F., Sofen, H., Abramovits, W., Zhao, Y., Gilloteau, I., Davenport, E., Williams, N., Guana, A., Tyring, S.
Publicado 2017

Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study

por Van Voorhees, A.S., Stein Gold, L., Lebwohl, M., Strober, B., Sofen, H., Papp, K., Bagel, J., Zhang, Z., Paris, M., Wang, Y.
Publicado 2021

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

por Blauvelt, A., Papp, K.A., Sofen, H., Augustin, M., Yosipovitch, G., Katoh, N., Mrowietz, U., Ohtsuki, M., Poulin, Y., Shrom, D., Burge, R., See, K., Mallbris, L., Gordon, K.B.
Publicado 2017

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermati...

por Bissonnette, R., Maari, C., Forman, S., Bhatia, N., Lee, M., Fowler, J., Tyring, S., Pariser, D., Sofen, H., Dhawan, S., Zook, M., Zammit, D.J., Usansky, H., Denis, L., Rao, N., Song, T., Pavel, A.B., Guttman‐Yassky, E.
Publicado 2019